Polynovo Ltd
PNV: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|$hTGhq< | LOCK|^^< | LOCK|$k>NmY@ |
Polynovo: Monthly Sales Tracking Well but Broadly in Line With Our Expectations
Polynovo’s fiscal 2025 EBITDA more than tripled to AUD 12 million compared with last year. Demand for its products is growing fast, with June 2025 monthly sales of AUD 13 million, up 8% on March 2025. Novosorb MTX in particular is gaining traction in the US after a fourth-quarter fiscal 2024 launch.
